A randomized, open label, single center, single-dose study to assess the effects of certain nasal medications on the pharmacokinetics, safety and tolerability of PMI-150 (intranasal ketamine hydrochloride) 30 mg

Trial Profile

A randomized, open label, single center, single-dose study to assess the effects of certain nasal medications on the pharmacokinetics, safety and tolerability of PMI-150 (intranasal ketamine hydrochloride) 30 mg

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 26 Feb 2008

At a glance

  • Drugs Ketamine (Primary) ; Antiallergics; Oxymetazoline; Steroids
  • Indications Allergic rhinitis; Pain
  • Focus Pharmacokinetics
  • Sponsors Javelin Pharmaceuticals
  • Most Recent Events

    • 26 Feb 2008 Status changed from recruiting to in progress as reported by Javelin.
    • 31 Aug 2007 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top